Medication Expected to Accumulate $125 in Revenue by 2033

A group of obesity and type 2 Diabetes drugs called GLP-1 receptor agonists have been released for use in therapy.

GLP-1 receptor agonist sales are rising along with the marketplaces for Type 2 diabetes and obesity, which are expanding at previously unheard-of rates.
During the following decade Type 2 Diabetes and Obesity will control the market for metabolic illnesses.

Key opinion leaders surveyed stated that consumers typically seek their doctors for these medications since they are already well-liked.

At present, 3 GLP-1 receptor agonists and ten GLP-1 receptor agonists for Type 2 diabetes are permitted; however, in the coming 5 to 10 years, numerous additional medications are anticipated to hit the shelves.